英菲格拉替尼和培米替尼的区别？

Infigratinib’s effects

Infigratinib blocks downstream signaling cascades by selectively binding to and inhibiting FGFR activity, reducing cancer cell proliferation and inducing tumor cell death. It is indicated for adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. It was approved for marketing by the US FDA in May 2021. It is an innovative, oral, ATP-competitive FGFR1-3 tyrosine kinase inhibitor.

Study CBGJ398X2204 (NCT02150967) was a multicenter, open-label, single-arm trial evaluating infigratinib in 108 patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, who were enrolled by local (89%) or central testing (11%).

The trial results showed that patients were given 125 mg orally once daily for 21 days and then stopped for 7 days in 28-day cycles until disease progression or unacceptable toxicity. The ORR (objective response rate) of patients after treatment was 23%, the median DoR (duration of response) was 5.0 months, and 32% of patients had DoR ≥6 months.

What are the effects of pemetinib?

Pemetinib is indicated as monotherapy for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements who have progressed after at least one prior line of systemic therapy. Pemetinib is a small, potent, and selective inhibitor of fibroblast growth factor receptor (FGFR) subtypes 1, 2, and 3.

FIGHT-202 (NCT02924376) was a multicenter, open-label, single-arm trial evaluating the efficacy of pemetinib in 107 patients with locally advanced unresectable or metastatic cholangiocarcinoma whose disease had progressed on or after at least 1 prior line of therapy and with FGFR2 gene fusion or nonfusion rearrangements as determined by clinical trial assays performed at a central laboratory. Trial results showed that the median DoR (duration of response) of patients was 9.1 months, and 24% of patients had DoR ≥ 6 months.

However, whether the patient should use infigratinib or pemetinib should be decided based on the doctor's diagnosis of the patient. Patients should not blindly take the drug and should follow the doctor's advice.

Recommended related articles: